Page 6 - Repligen Co News Today

Ledyard National Bank trimmed its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 4.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,933 shares of the biotechnology company’s stock after selling 944 shares during the period. Ledyard National Bank’s […]

Repligen Co. (NASDAQ:RGEN – Free Report) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $142.56 and last traded at $142.78, with a volume of 73224 shares changing hands. The stock had previously closed at $150.57. Analyst Upgrades and Downgrades RGEN has been the subject of […]

Shares of Repligen Co. (NASDAQ:RGEN – Get Rating) have received a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among […]

American Capital Management Inc. boosted its position in Repligen Co. (NASDAQ:RGEN – Get Rating) by 14.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 140,751 shares of the biotechnology company’s stock after purchasing an additional 17,827 shares during the quarter. American […]

American Capital Management Inc. lifted its holdings in Repligen Co. (NASDAQ:RGEN – Get Rating) by 14.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 140,751 shares of the biotechnology company’s stock after buying an additional 17,827 shares during the quarter. American Capital Management Inc. […]

The Manufacturers Life Insurance Company boosted its position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 1.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 55,557 shares of the biotechnology company’s stock after acquiring an additional 695 shares during the […]

Pitcairn Co. lowered its stake in Repligen Co. (NASDAQ:RGEN – Get Rating) by 6.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,263 shares of the biotechnology company’s stock after selling 290 shares during the period. Pitcairn Co.’s holdings in Repligen […]

Shares of Repligen Co. (NASDAQ:RGEN – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month target price among […]

First Trust Advisors LP grew its stake in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 197.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 135,191 shares of the biotechnology company’s stock after buying an additional 89,724 shares during the period. First Trust […]

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 6.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 170,205 shares of the biotechnology company’s stock after purchasing an additional 11,028 shares during the […]